Kamada (KMDA) Change in Accured Expenses (2012 - 2026)
Kamada's (KMDA) quarterly Change in Accured Expenses came in at -$1.9 million in Q1 2026, up 7.19% YoY from -$1.8 million in Q1 2025, and down 257.69% on a QoQ basis from $1.2 million in Q4 2025.
Kamada (KMDA) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Kamada (KMDA) has 15 years of Change in Accured Expenses data on file, last reported at -$1.9 million in Q1 2026.
- Quarterly Change in Accured Expenses rose 7.19% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 22.75% YoY) and the FY2025 annual result came in at $950000.0, down 32.77% from the prior year.
- Change in Accured Expenses retreated to -$1.9 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $1.6 million in Q4 2024 to a low of -$2.1 million in Q1 2024.
- A 5-year average of -$2731.2 and a median of $2083.0 in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 407346.38% — and 2024, when it tumbled 861664.71%.
- Tracing KMDA's Change in Accured Expenses over 5 years: stood at -$276.0 in 2022, then soared by 407346.38% to $1.1 million in 2023, then jumped by 39.68% to $1.6 million in 2024, then slipped by 23.38% to $1.2 million in 2025, then slumped by 257.69% to -$1.9 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.9 million (Q1 2026), $1.2 million (Q4 2025), and $630000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Kamada | 464.63 Mn | 435.16 Mn | 22.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.81 Mn |
| Jun 30, 2026 | 1.81 Mn |
| Mar 31, 2026 | -1.90 Mn |
| Mar 31, 2026 | -1.90 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 630,000.00 |
| Sep 30, 2025 | 630,000.00 |
| Jun 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | -2.04 Mn |
| Mar 31, 2025 | -2.04 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 881,000.00 |
| Sep 30, 2024 | 881,000.00 |
| Jun 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.05 Mn |